我是 LongbridgeAI，我可以總結文章信息。Schall, Brown & Schwartz LLP 正在調查 Ionis Pharmaceuticals (NASDAQ: IONS) 是否存在潛在的證券法違規行為。該調查旨在審查公司是否發佈了誤導性聲明或未能披露與其 Wainua 的第三階段 CARDIO-TTransform 試驗相關的重要信息，該試驗於 2026 年 7 月 9 日未能達到主要終點，導致股價下跌 23.9%。遭受損失的投資者被鼓勵聯繫該公司以討論他們的權利
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or “the Company”) (NASDAQ: IONS) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ionis revealed on July 9, 2026, that its late-stage Phase-3 CARDIO-TTransform trial of Wainua failed to meet its primary endpoint. Based on this news, shares of Ionis fell by 23.9% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at david@schallfirm.com
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260808352745/en/